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Prospective, placebo-controlled clinical trials suggest that
estrogen may have adverse effects on the vascular system
in women. The goal of this study was to determine if
17b-estradiol (E2) would have adverse effects on the
renovasculature in a rat model of renal injury characterized
by low nitric oxide (NO) and high angiotensin II (AngII). We
studied female Wistar rats that were sham-operated (sham),
ovariectomized (OVX), or ovariectomized and replaced with
E2 (OVX/E2). All rats were maintained on a high salt diet and
renovascular injury was caused by treating rats with an
inhibitor of NO synthase, Nx-nitro-L-arginine-methyl-ester
(L-NAME), for 14 days, plus AngII on days 11 through 14.
L-NAME/AngII treatment, as compared to placebo, caused
proteinuria, glomerular injury, and fibrinoid necrosis of renal
arterioles in sham-operated rats. Ovariectomy reduced
L-NAME/AngII-induced renal damage, whereas E2 treatment
increased L-NAME/AngII-induced damage in OVX rats. In rats
treated with L-NAME/AngII, levels of AngII type 1 receptor
(AT1R) protein were higher in the renal cortex of sham and
OVX/E2 rats than in OVX rats. AT1R protein correlated with
renal injury. E2 treatment also increased expression of AT1R
mRNA. Thus, under conditions of low NO and high AngII,
E2 exacerbated renal injury. E2-mediated increases in renal
cortical AT1R expression may represent a novel mechanism
for the adverse renovascular effects of estrogen.
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Many observational studies show beneficial cardiovascular
effects with hormone replacement therapy.1–3 However, large-
scale, prospective clinical studies suggest that estrogen with
and without progestin may not be beneficial and may
contribute to vascular pathology. In the Heart and Estrogen/
progestin Replacement Study, hormone replacement therapy
failed to provide benefit in women with established coronary
heart disease.4 The Women’s Health Initiative showed that,
compared with placebo, estrogen replacement therapy, alone
or with progestin, is associated with an increased risk for
vascular disease in postmenopausal women.5,6 These adverse
effects on the vasculature appeared to be widespread as
increases in coronary events, stroke, and pulmonary
embolism were observed. It has been suggested that these
adverse effects of hormone replacement therapy occur in
women with underlying cardiovascular disease.7
Microalbuminuria is an indicator of renal vascular injury
and is a predictor of cardiovascular disease.8 In Heart and
Estrogen/progestin Replacement Study, renal injury was a
strong predictor of peripheral arterial disease events.9 A few
studies have examined the effect of estrogen with and without
progestin on microalbuminuria in women. One study
showed no effect of estrogen plus progestin on microalbu-
minuria in postmenopausal women with type II diabetes.10
In contrast, microalbuminuria was increased in premeno-
pausal women using oral contraceptives and in postmeno-
pausal women receiving hormone replacement therapy as
compared with women not receiving these medications.11,12
Oral contraceptive use also increased the risk of macro-
albuminuria in women with diabetes.13 In healthy women
and in women with diabetes, oral contraceptive use was
associated with an exaggerated renal blood flow response to
acute administration of an angiotensin-converting enzyme
inhibitor or an angiotensin receptor blocker, suggesting that
oral contraceptives lead to increased angiotensin II (AngII)
activity in the renal circulation.13
The goal of this study was to determine if 17b-estradiol
(E2) would have adverse effects on the renovasculature in
a rodent model of renal injury, and if it did, by what
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mechanisms. We chose a model of renal injury that is
dependent on low nitric oxide (NO) and on the presence of a
well-known mediator of renal injury, AngII. Low NO and
high AngII are commonly observed in patients with
hypertension.14 In this animal model of renal injury, rats
on a high-sodium diet receive the NO synthase inhibitor
No-nitro-L-arginine-methyl-ester (L-NAME) for 14 days and
AngII for the last 3 days, resulting in the development of
proteinuria, glomerular injury, and fibrinoid necrosis of renal
arterioles.15 Using this model, we examined the effects of
ovariectomy and E2 replacement on proteinuria, renal
histopathology, and renal cortical expression of AngII type
1 receptor (AT1R) protein and mRNA.
RESULTS
L-NAME/AngII and renal injury
We studied five groups of female Wistar rats: sham-operated
rats receiving placebo (control treatment), sham-operated
rats receiving L-NAME/AngII, ovariectomized (OVX) rats
receiving control treatment, OVX rats receiving L-NAME/
AngII, and OVX rats receiving L-NAME/AngII plus E2. All
rats received 1% NaCl to drink. Rats were killed at the end of
the 14-day treatments without respect to timing of the 4-day
estrous cycle and blood was collected for determination of E2
levels. Thus, there was a wide range of E2 levels in the 18
sham-operated rats (range 5–45 pg/ml, mean 16.872.6 pg/
ml). The mean E2 level in the 18 OVX rats not receiving E2
(8.972.3 pg/ml) was significantly lower than that observed in
the sham-operated rats (Po0.01 by Student’s t-test). E2 levels
were significantly higher in OVX rats receiving E2 as
compared with OVX rats receiving placebo (Table 1).
Consistent with their low-estrogen status, OVX rats had
higher body weights, lower uterine weights, and lower
uterine/body weight ratios than sham-operated rats and
E2-treated OVX rats (Table 1). L-NAME/AngII treatment, as
compared to control treatment, increased systolic blood
pressure (BP) and this increase in BP was similar in sham-
operated OVX and OVX/E2 groups (Figure 1a and Table 1).
In sham-operated rats, proteinuria measured on day 14
was 20-fold higher with L-NAME/AngII treatment as
compared with control treatment (Figure 1b and Table 1).
This result was not due to differences in urine collections, as
24-h urinary creatinine excretion was similar across groups.
Histological evaluation of kidneys from L-NAME/AngII-
treated rats revealed glomerular damage and renal vascular
injury characterized by perivascular inflammation and
Table 1 | Effect of L-NAME/AngII and E2 treatments on metabolic measurements and histological assessment of renal vascular
injury in sham and OVX rats
Control L-NAME/AngII
Sham OVX Sham OVX OVX/E2
(n=8) (n=8) (n=10) (n=10) (n=10)
BW (g)
Day 8 24277 27475a 25673 27374a 27673a
Day 14 28873 33577a 28075 31379a 26074b
UW
UW(g) 0.8870.05 0.2270.02a 0.7970.06 0.2470.02a 0.9170.1b
UW/BW (mg/g) 30.771.5 6.570.5a 28.472.3 7.870.5a 35.074.4b
Estradiol (pg/ml) 12.872.6 9.972.0 20.074.1 871.7 141735a,b,c,d
Systolic blood pressure (mm Hg)
Day 1 12176 11773 11174 10875 10374
Day 14 12274 12675 15978c 15376d 16479d
24-h urine measurements
Total protein (mg/day)
Day 1 10.170.7 15.776.8 10.471.9 9.571.1 11.071.5
Day 14e 8.570.9 7.070.4 167.0735.3c 85.2734.4a 212.4738.8b,d
Creatinine (mg/day)
Day 1 8.671.3 9.471.1 9.371.3 14.071.8 10.371.1
Day 14e 8.671.4 9.871.8 10.071.6 14.275.0 7.771.0
Histological assessment of renal damage
Renal vascular injury score (number of injured vessels per 100 glomeruli) 070 0.670.3 7.371.4b,c,d 1.670.5a 8.171.3b,c,d
Number of glomeruli (per section) 391711 372711 363715 347713 369723
AngII, angiotensin II; BW, body weight; L-NAME, No-nitro-L-arginine-methyl-ester; OVX, ovariectomized; OVX-E2, ovariectomized and replaced with E2; UW, uterine weight.
aPo0.05 vs sham group receiving same treatment.
bPo0.05 vs OVX group receiving L-NAME/AngII treatment.
cPo0.05 vs sham group receiving control treatment.
dPo0.05 vs OVX group receiving control treatment.
en=6–8 per group.
Data given as mean7s.e.
1760 Kidney International (2006) 70, 1759–1768
o r i g i n a l a r t i c l e EM Oestreicher et al.: Estradiol increases proteinuria
fibrinoid necrosis (Figure 2). Scoring of the renal vascular
injury revealed significant damage in L-NAME/AngII-treated,
sham-operated rats compared with control-treated, sham-
operated rats (Table1 and Figure 1c).
Ovariectomy significantly reduced L-NAME/AngII-in-
duced proteinuria and renal vascular injury. The protective
effect of ovariectomy was completely reversed by adminis-
tration of E2 (Figure 1b and c, and Table 1). Compared with
OVX rats not receiving E2, OVX rats with E2 replacement
had a significant increase in L-NAME/AngII-induced renal
injury, as measured by both proteinuria and kidney vascular
injury score. The extent of L-NAME/AngII-induced renal
injury in OVX/E2 rats was comparable to that in the sham-
operated, L-NAME/AngII-treated rats.
Within the L-NAME/AngII-treated groups, OVX rats had
significantly lower levels of AT1R protein in the renal cortex
than both the sham-operated and OVX/E2 groups (Figure 3b
and c). Furthermore, in all groups of L-NAME/AngII-treated
rats, the level of AT1R protein correlated positively with
urinary protein excretion on day 14 (r2¼ 0.52, Po0.001)
(Figure 3d) and with the renal vascular injury score
(r2¼ 0.24, Po0.01).
Effect of estrogen status on relationship between renal
injury, lipid levels, AT1R protein, and mRNA levels
of AT1AR and AT1BR
A second set of studies was performed in order to determine,
in the same animals, the effects of our treatments on renal
cortical levels of AT1R protein, AT1AR mRNA and AT1BR
mRNA, and on hyperlipidemia, a potential mediator of the
adverse effects of E2.16–18 We studied OVX rats receiving one
of three treatments: (1) placebo (control treatment); (2)
L-NAME/AngII; and (3) L-NAME/AngII plus E2. All rats
received drinking water containing 1% NaCl. Rats were fed a
phytoestrogen-free diet as phytoestrogens have been shown
to mimic the effects of estrogen19 and we wanted to minimize
factors that could potentially confound our results. OVX rats
not receiving E2 had lower serum E2 levels, weighed more,
and had uterine atrophy compared with those receiving E2
(Table 2). As observed in the first study, E2 treatment did
not influence significantly the L-NAME/AngII-induced rise
in systolic BP, but significantly increased proteinuria in
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Figure 1 | Effect of estrogen status on systolic BP, proteinuria,
and renal vascular injury score in rats receiving L-NAME/AngII or
control treatment. Sham-operated (Sh) or OVX female rats drinking
1% NaCl received either the 14-day L-NAME/AngII treatment (gray
bars) or control treatment (white bars). Rats were further randomized
to receive E2 or placebo starting 1 week before L-NAME/AngII
treatment. (a) Systolic BP was measured over the course of the study.
(b) Twenty-four hour urinary protein excretion and (c) renal vascular
injury score expressed as number of injured vessels per 100 glomeruli
were measured at the end of the 14-day treatment. **Po0.001
compared with control treatment. Control treatment groups: n¼ 8
for BP, n¼ 7–8 for urinary protein and renal vascular injury score.
L-NAME/AngII treatment groups: n¼ 10 for BP, n¼ 6–8 for urinary
protein, n¼ 8–9 for renal vascular injury score. Data given as
mean7s.e.
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Figure 2 | Renal histopathology of rats receiving L-NAME/AngII
and control treatments. Representative sections of (a and b)
damaged kidney from L-NAME/AngII-treated rats and (c and d)
normal kidney from control-treated rats. Right side of renal arteriole
(Art) in panel (a) shows early, localized fibrinoid necrosis (FN) with
destruction of the muscular layer, perivascular edema (PE), and
perivascular inflammatory cell infiltrates. Glomerulus (G) in panel (b)
shows segmental fibrinoid necrosis of the glomerular tuft and
mesangiolysis. Tubules (T) in panel (b) have debris casts indicating
tubular injury. Bar¼ 100 mm.
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L-NAME/AngII-treated rats (Table 2). Creatinine clearance
was similar in all three groups. E2 treatment did not alter
levels of total cholesterol, high-density lipoprotein, low-
density lipoprotein, and triglyceride.
Renal cortical levels of AT1R protein were determined by
Western blot analysis using two distinct antibodies, a mouse
monoclonal antibody ab9391 from Abcam Inc. (Cambridge,
MA, USA) and a rabbit polyclonal antibody sc-1173 from
Santa Cruz Biotechnologies Inc. (Santa Cruz, CA, USA), with
similar results (Figure 4a and b). Renal cortical levels of AT1R
protein were significantly higher in the E2/L-NAME/AngII-
treated OVX rats compared with OVX rats receiving
L-NAME/AngII and with OVX rats receiving control treatment.
We examined mRNA expression in renal cortex of AT1AR
and AT1BR, the two subtypes of AT1R in rodents. The levels
of AT1AR mRNA in L-NAME/AngII-treated OVX rats
receiving E2 were significantly elevated compared with those
in control-treated OVX rats and L-NAME/AngII-treated OVX
rats not receiving E2 (Figure 4c). The level of AT1BR mRNA
was highest in the OVX rats receiving E2/L-NAME/AngII
and was significantly greater than that observed in estrogen-
deficient, OVX rats receiving control treatment (Figure 4d).
The level of AT1R protein assessed with the mouse
monoclonoal antibody correlated with the amount of AT1AR
mRNA (r2¼ 0.58, Po0.001) and with the extent of
proteinuria (r2¼ 0.40, Po0.03).
Expression of estrogen receptor-a, estrogen receptor-b, and
AT1R in female rat kidney cortex
Confocal microscopy showed expression of estrogen receptor
(ER)-a, ER-b, and AT1R in the arterioles and glomeruli of the
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Figure 3 | Effect of L-NAME/AngII and E2 treatments on AT1R
protein content in renal cortex. (a) Western blot of rat renal cortical
tissue (Kdn) (40 mg/lane) probed with the rabbit monoclonal AT1R
antibody N-10 (sc-1173P). The three lanes on the right were
incubated with the AT1R-blocking peptide before addition of the
AT1R antibody N-10. A positive control for AT1R protein (Ctl) (12.5 mg/
lane of PC-12 lysate (sc-2250, Santa Cruz)) was run in the first and
fourth lanes. The AT1R antibody detected in rat renal cortex two
bands with molecular weights of approximately 43 and 49 kDa. The
relative intensities of these two bands varied between animals within
the same experimental condition. These bands are thought to
represent different extents of glycosylation.38 Neither band was
observed when the AT1R-blocking peptide was used, showing the
specificity of the N-10 antibody for AT1R. AT1R-blocking peptide did
not block detection of ERa (data not shown). (b) Representative
Western blot of renal cortical tissue (40 mg of protein per lane)
showing 43 and 49 kDa bands for AT1R in the different study groups.
Lanes 1–2, control treatment; lanes 3–5, L-NAME/AngII treatment;
lanes 1 and 3, sham-operated rats; lanes 2, 4–5, OVX rats. (c) Relative
levels of AT1R protein in renal cortex of the different study groups.
n¼ 5 in sham/control, n¼ 7 in OVX/control and in L-NAME/AngII-
treated rats, n¼ 8 sham, n¼ 8 OVX, n¼ 6 OVX/E2. Data given as
mean7s.e. (d) AT1R protein content in renal cortex plotted vs 24-h
urinary protein for individual rats in sham (n¼ 8), OVX (n¼ 6), and
OVX/E2 (n¼ 6) groups receiving L-NAME/AngII. AT1R content
correlates with proteinuria, r2¼ 0.52; Po0.001. Linear regression line
is shown.
Table 2 | Effect of L-NAME/AngII and E2 treatments on
metabolic measures in OVX rats.
Control
L-NAME/AngII
OVX OVX OVX/E2
(n=8) (n=8) (n=8)
Systolic blood pressure (mm Hg) 11175 15377a 15875a
Uterine weight/body weight (mg/g) 3.170.06 3.370.04 27.273a,b
Body weight (g) 32477 30873 25178a,b
Serum measurements
Estradiol (pg/ml) 9.671.3 11.271 1917120a,c
Creatinine (mg/dl) 0.3670.1 0.3470.1 0.3570.1
Lipid profile
Triglyceride (mg/dl) 160717 133722 175735
Cholesterol (mg/dl) 12279 11774 12277
HDL (mg/dl) 4873 4571 4272
LDL (mg/dl) 1571 1571 1771
24 h urine measurements
Total protein (mg/day) 5.170.6 5.871.3 21.579.6a,c
Creatinine (mg/day) 11.472 16.473 12.272
Creatinine clearance (ml/min) 0.870.1 0.9970.2 0.6970.1
AngII, angiotensin II; E2, 17b-estradiol; HDL, high-density lipoprotein; LDL, low-
density lipoprotein; L-NAME, No-nitro-L-arginine-methyl-ester; OVX, ovariectomized.
aPo0.01 vs OVX group receiving control treatment.
bPo0.01 vs OVX group receiving L-NAME/AngII treatment.
cPo0.05 vs OVX group receiving L-NAME/AngII treatment.
Data given as mean7s.e.
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renal cortex of sham-operated, control-treated rats (Figure 5).
Merged images showed colocalization of both types of
estrogen receptors with the AT1R. In addition, AT1R
immunoprecipitates from renal cortex homogenates were
analyzed by Western blot using antibodies specific to ER-a
and ER-b. Figure 6b shows that immunoprecipitation of
AT1R co-precipitates ER-a and ER-b. These studies suggest a
close association of the AT1R with both estrogen receptors.
DISCUSSION
Under conditions of high AngII and low NO, female rats
developed hypertension and kidney damage characterized by
proteinuria, glomerular injury, and renal vascular injury.
Ovariectomy reduced this renal damage, whereas the
administration of E2 to OVX rats increased damage.
Estrogen-replete, L-NAME/AngII-treated animals had in-
creased renal cortical expression of AT1R protein compared
with estrogen-deficient OVX rats receiving L-NAME/AngII.
Furthermore, the amount of AT1R protein correlated with the
extent of L-NAME/AngII-induced proteinuria and renovas-
cular injury. These results suggest that under conditions of
low NO availability and high AngII, E2 increased the
expression of AT1R, leading to increased AngII-mediated
renal injury. Estrogen-mediated increases in expression of
AT1R may represent a novel mechanism by which E2
increases renal injury and could have widespread implica-
tions, given the critical role of AngII in mediating
cardiovascular injury in general.
Studies in OVX rats examining the effects of estrogen
treatment on renal function have demonstrated both
beneficial and adverse effects. These differing results may be
related to differences between rat strains and experimental
models. Estrogen reduced proteinuria and/or glomerulo-
sclerosis in the OVX rat remnant kidney model,20 the OVX
rat with streptozotocin-induced diabetes,21 and the OVX,
aging Dahl salt sensitive rat fed a low sodium diet.22 In
addition to the present model, administration of estrogen to
OVX female rats increased proteinuria and glomerular injury
in: (1) the obese Zucker rat;18 (2) the uninephrectomized
hyperlipidemic analbuminemic rat;16 (3) the spontaneously
hypercholesterolemic female Imai rat;17 and (4) in some,23
but not all24 studies the stroke-prone spontaneously
hypertensive rat.
In some models of renal injury, estrogen-induced
increases in hyperlipidemia are hypothesized to contribute
to the increase in renal injury observed with estrogen
treatment.16–18 In the current studies, E2 treatment did not
alter lipid levels in L-NAME/AngII-treated rodents, suggest-
ing that the increase in renal injury with E2 was not mediated
by changes in lipids. In addition, estrogen status did not
influence the effect of L-NAME/AngII on systolic BP,
suggesting that the adverse effects of estrogen on proteinuria
were not mediated by changes in systemic BP.
In L-NAME/AngII-treated rats, levels of AT1R protein in
the renal cortex were reduced by ovariectomy and increased
by E2 treatment. E2 also increased renal cortical levels of
AT1AR mRNA in OVX rats treated with L-NAME/AngII.
Furthermore, renal cortical levels of AT1R protein correlated
with both proteinuria and the renovascular injury score.
Thus, in this AngII-dependent model of renal injury, E2
appeared to increase renal injury by increasing the expression
of AT1R. Similarly, estrogen has been reported to increase
AT1R protein in renal medullary rays
25 and in uteri of healthy
OVX rats.26 In contrast, estrogen has been reported to
decrease AT1R protein in other tissues such as rat adrenal,
26,27
vascular smooth muscle,28 pituitary26,29 and myocardium.30
Thus, the effect of estrogen on expression of AT1R protein
may be tissue specific and/or depend on other factors such as
NO and AngII.
These studies do not allow us to determine whether the
effect of E2 on AT1R expression is direct or indirect. It is well
known that E2 has effects on components of the renin–an-
giotensin–aldosterone system. E2 increases expression of
angiotensinogen.31 Thus, the E2 effects on AT1R could be
indirect and secondary to E2-mediated increases in angio-
tensinogen, leading to increased AngII. However, if this were
to occur, we would expect a compensatory decrease in AT1R.
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Figure 4 | Effect of E2 on renal cortical levels of AT1R protein,
AT1AR mRNA, and AT1BR mRNA in L-NAME/AngII-treated OVX
rats. (a) Representative Western blot probed with mouse monoclonal
antibody ab9391 and graph quantifying AT1R protein in the three
treatment groups – OVX rats receiving control treatment, OVX rats
receiving L-NAME/AngII, and OVX rats receiving E2 plus L-NAME/
AngII. (b) Representative Western blot probed with rabbit polyclonal
antibody sc-1173 and graph quantifying AT1R protein in the three
treatment groups showing results similar to those with the antibody
ab9391. (c) AT1AR mRNA and (d) AT1BR mRNA levels in the three
groups. mRNA levels are expressed relative to b-actin mRNA levels.
N¼ 8 per group. Data given as mean7s.e.
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Instead, we saw an increase. To begin to address the
possibility that there could be a direct effect of E2 on
AT1R, we used confocal microscopy and immunoprecipita-
tion studies to determine if the estrogen receptors and AT1R
are expressed in the same cells. Because these studies were
positive, this suggests E2 may have a direct effect on AT1R
expression. Further studies are needed to address this
possibility.
Several studies show an adverse effect of estrogen-
containing oral contraceptives and estrogen–progestin repla-
cement therapy on renal vascular injury in women. A study
involving over 100 women revealed an increased risk of
microalbuminuria in women who used estrogen–progestin
oral contraceptives compared with those who did not use oral
contraceptives.11 Similarly, a case–control study of over 4000
women showed that, after adjusting for age, hypertension,
diabetes, obesity, hyperlipidemia, and smoking, the risk of
microalbuminuria was increased in pre- and post-menopau-
sal women who used estrogen–progestin therapy and that the
risk increased with the duration of hormone replacement
therapy in postmenopausal women who used hormone
replacement therapy.12 In healthy, premenopausal women,
use of estrogen-containing oral contraceptives for at least
3 months was associated with an increase in both renal
vascular resistance and filtration fraction as compared with
values in women not using oral contraceptives.32 Finally, a
recent study examined the effect of oral contraceptive use on
renal blood flow and activity of the renin–angiotensin system
in premenopausal women with and without diabetes.13 The
oral contraceptive users, as compared to non-users, had a
greater increase in renal blood flow with acute administration
of an angiotensin-converting enzyme inhibitor suggesting
that there is increased activity of the renin–angiotensin
system in the renovasculature of women with and without
diabetes who use oral contraceptives. This result is consistent
with our current finding of increased renal expression of
AT1R protein and mRNA with E2 treatment of rats receiving
L-NAME/AngII.
There are several limitations to the current studies. First,
E2 treatment was started 7–10 days after ovariectomy. It is
possible there were changes in gene expression during this
period of estrogen deficiency that were not reversed by
initiation of estrogen replacement. Second, we administered
E2 continuously achieving average E2 levels of 140–190 pg/
ml, whereas E2 levels fluctuate in cycling female rats peaking
at 50–150 pg/ml in proestrus (reviewed by Becker et al.33).
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Figure 5 | Confocal microscopy of AT1R, ER-a, and ER-b in renal cortex. Renal cortical tissue sections from female rats drinking 1% NaCl for
14 days were co-immunostained with fluorescent antibodies to (a and i) AT1R and (b and j) ER-a and to (e and m) AT1R and (f and n) ER-b. AT1R,
ER-a, and ER-b are expressed in (a–d and e–h) glomeruli and (i–l and m–p) renal vessels. In glomeruli, AT1R colocalized with both (c and d) ER-a
and (g and h) ER-b. In renal arterioles, AT1R colocalized (o and p) with ER-b but showed little colocalization (k and l) with ER-a.
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It is possible that, in L-NAME/AngII-treated rats, continuous
levels of E2 in the high physiological range could have
different effects on renovascular injury than transient
exposures to similar levels of E2 in cycling rats. However,
cycling female rats are exposed repeatedly, every 4–5 days, to
the high E2 levels observed in proestrus. In addition, some
studies report prolonged physiological effects of transient
increases in circulating E2 (reviewed by Becker et al.33). Thus,
although the current studies demonstrated an adverse
renovascular effect of E2 in the 2-week L-NAME/AngII
model, longer time periods may be necessary to demonstrate
an effect, or the effect may not occur, under conditions of
cycling E2 levels or lower continuous doses of E2. Third, we
have not examined the effects of different modes of E2
administration on our endpoints. Fourth, although the
effects of OVX and E2 treatment are of similar magnitude
on renal injury and AT1R expression in L-NAME/AngII-
treated rats, these studies do not rule out the possibility that
E2 has effects that are independent of those of OVX. For
example, ovariectomy results in progesterone deficiency, and
we have not examined the effects of progesterone on renal
injury in this model.
By manipulating the estrogenic status of female rats
through ovariectomy and estradiol replacement, we showed
that the estrogen-replete state was associated with increased
renal vascular injury and proteinuria in hypertensive,
L-NAME/AngII-treated rats consuming a moderately high
sodium diet. Increased renal damage appeared to be
mediated by increased expression of AT1R in the renal
cortex. Because of the key role of AngII in mediating renal
injury in humans, these findings could have important
implications for woman’s health, particularly for disease
states associated with low NO and high AngII levels such as
hypertension.
MATERIALS AND METHODS
Experimental animals
Experiments used 10-week-old female Wistar rats (Charles River
Lab, Wilmington, MA, USA) that underwent bilateral ovariectomy
(OVX) or sham-operation (sham) at 8 weeks of age. Rats had ad
libitum access to drinking fluid. They were housed in individual
metabolic cages in a climate-controlled environment (22711C)
with a 12-h light, 12-h dark cycle. All experimental procedures met
guidelines of the Institutional Animal Care and Use Committee at
Harvard University.
Experimental procedures
Two animal studies were performed. In study 1, we examined five
groups of rats receiving Purina Lab Chow 5001 (Ralston Purina Co.,
St Louis, MO, USA) and 1% NaCl to drink: (1) sham-operated rats
implanted with pellets containing placebo and receiving control
treatment (no L-NAME and minipumps containing vehicle), n¼ 8;
(2) OVX rats implanted with pellets containing placebo and receiving
control treatment, n¼ 8; (3) sham-operated rats implanted with
pellets containing placebo and receiving L-NAME/AngII treatment,
n¼ 10; (4) OVX rats implanted with placebo pellets and receiving
L-NAME/AngII treatment, n¼ 10; and (5) OVX rats implanted with
E2 pellets and receiving L-NAME/AngII treatment, n¼ 10. In study 2,
we examined three groups of rats receiving a phytoestrogen-free
diet (No. D10001, Research Diets Inc., New Brunswick, NJ, USA)
and 1% NaCl to drink: (1) OVX rats implanted with pellets
containing placebo and receiving control treatment, n¼ 8; (2) OVX
rats implanted with placebo pellets and receiving L-NAME/AngII
treatment, n¼ 8; and (3) OVX rats implanted with E2 pellets and
receiving L-NAME/AngII treatment, n¼ 8.
Pellets containing E2 (0.5 mg/pellet, 21-day release, No. E121,
Innovative Research of America, Sarasota, FL, USA) or placebo (No.
C111, Innovative Research of America) were implanted subcuta-
neously in each rat 7–10 days after ovariectomy or sham operation.
E2 levels rise to 50–150 pg/ml during proestrus.33 The 0.5 mg, 21-day
E2 pellets raise plasma estradiol levels to this range.34–36 One week
after implantation of the pellets, animals were treated with L-NAME/
AngII as previously described.15,37 Briefly, rats received 1% NaCl in
drinking water or 1% NaCl plus L-NAME. L-NAME (Sigma, St
Louis, MO, USA) (40 mg/kg/day) was administered for 14 days
either through the drinking water (study 1) or via a subcutaneously
implanted pellet (Innovative Research of America) (study 2). Vehicle
or AngII (Sigma) (0.225 mg/kg/day) was administered via Alzet
osmotic minipumps (Model 2001, Durect Corporation, Cupertino,
CA, USA) (1.0 ml/h, 7 days) for the final 3 days. On day 14, rats were
anesthetized with isoflurane and blood and tissue samples were
harvested.
Measurements and assays
Daily food intake, water intake, body weight, and urine output were
recorded. Systolic BP was measured in conscious animals by tail-cuff
plethysmography (Blood Pressure Analyzer, Model 179, IITC Life
Western blot analysis of kidney
AT1 R immunoprecipitates
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66 kDa
Kdn CtlCtl
ER- probe
55 kDa
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Western blot of ER- and ER-
66 kDa
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ER- ER- Kdn
ER- probe ER- probe
Ctl Ctl
ER-ER- Kdn
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Figure 6 | Expression of AT1R, ER-a, and ER-b in renal cortex.
(a) Western blot of rat renal cortical tissue (Kdn) (40mg/lane),
recombinant ER-a (ER-a Ctl), and recombinant ER-b (ER-b Ctl) probed
with antibodies specific to ER-a (left panel) and ER-b (right panel).
The ER-a antibody detected a 66-kDa band in rat kidney that
corresponded to the size of the recombinant ER-a control. The
ER-b antibody detected a 55-kDa band in rat kidney that
corresponded to the size of the recombinant ER-b control. There
was no cross reactivity. (b) Representative Western blot analysis
of AT1R immunoprecipitates of kidney cortical homogenates (Kdn)
probed for ER-a (left panel) and ER-b (right panel) showing
co-immunoprecipitation of AT1R with both ER-a and ER-b.
Recombinant ER-a and ER-b proteins were run as positive
controls (Ctl) in right lane of the corresponding blot.
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Science, Woodland Hills, CA, USA).15 Protein was measured in
urine with the Coomasie Plus protein assay (Pierce, Rockford, IL,
USA). Creatinine was measured using the ACE creatinine reagent
(Alfa Wassermann Inc., West Caldwell, NJ, USA). Serum estradiol
was measured with the DPC Double Antibody Estradiol radio-
immunoassay (DPC Diagnostic Products, Los Angeles, CA, USA).
Lipid levels were detected using ACE lipid panel reagents (Alfa
Wasserman). The lipid panel consists of an enzymatic and
colorimetric assay for total cholesterol (No. SA1010) and for tri-
glycerides (No. SA1023), and a homogeneous enzymatic colorimetric
method for high-density lipoprotein (No. SA1015) and low-density
lipoprotein (No. SA1018).
Tissue processing and histological evaluation
One kidney per rat was frozen immediately after collection and
stored in liquid nitrogen until processing for Western blot analysis
and mRNA studies. The other kidney was processed into paraffin
blocks. Coronal kidney sections (5mm) stained with hematoxylin
and eosin or periodic acid-Schiff reagent were examined by light
microscopy by a pathologist unaware of the treatment group
assignment. Renal arterial and arteriolar damage was defined as the
presence of fibrinoid necrosis of the vascular wall irrespective of
magnitude of damage in a given vessel. Renal vascular injury was
assessed by counting the total number of profiles of damaged
arteries and arterioles per mid-coronal section, and dividing by the
total number of glomeruli in the same section to normalize for the
amount of tissue examined. Vascular injury score was expressed as
the number of injured vessels per 100 glomeruli.
Western blot analysis
The kidney cortex was dissected on ice and homogenized in ice-cold
2-(N-morpholino) ethanesulfonic acid (MES) buffer, pH 6.5 (25 mM
MES (Sigma), 150 mM NaCl, 1% Triton X-100, 5 mM ethylene glycol-
bis(b-aminoethyl ether)-N,N,N’,N’-tetraacetic acid) containing
1 mM sodium orthovanadate, the protease inhibitor cocktails
P8340 (Sigma) and P2714 (Sigma) each 0.3 ml/10 ml homogenate
buffer and the phosphatase inhibitor cocktails P-5726 and P-2850
each 0.3 ml/10 ml homogenate buffer. Homogenates were centri-
fuged at 11 000 r.p.m. for 10 min at 41C and the supernatants
collected on ice. Protein concentration in the supernatant was
determined using a Micro bicinchoninic acid protein reagent kit
(Pierce). Supernatants (40 mg of protein) were combined with an
equal volume of 2 laemmli-loading buffer (250 mM Tris, pH 6.8,
10% sodium dodecyl sulfate, 50% glycerol, 0.1% pyronin, 200 mM
dithiothreitol), boiled for 5 min, and size fractionated by electro-
phoresis on 10% sodium dodecyl sulfate-polyacrylamide gels.
Proteins were electrophoretically transferred to nitrocellulose
membranes (Schleicher and Schuell, Keene, NH, USA). The
membranes were blocked in 5% non-fat dried milk in phosphate-
buffered saline (PBS) (150 mM NaCl, 1.9 mM NaH2PO4, 8.1 mM
Na2HPO4 anhydride, and 0.2% Triton X-100), and incubated
overnight at 41C with 1:500 AT1R antibody (rabbit polyclonal
antibody N-10; sc-1173, Santa Cruz Biotechnology Inc. or mouse
monoclonal antibody ab9391 (Abcam Inc.) to detect AT1R. We
demonstrated excellent correlation between levels of AT1R protein in
rat tissue as determined by radioligand binding with AngII-labeled
((125I)(Sar1, Ile8) and Western blot analysis using either AT1R
antibody, ab9391 (R¼ 0.7, Po0.0001), and sc-1173 (R¼ 0.47,
Po0.0001). In addition, for the sc-1173 antibody, additional
membranes were incubated overnight with 100 mg of the
AT1R-blocking peptide (N-10P, No. sc-1173P, Santa Cruz Biotech-
nology Inc.). Sc-2250 (Santa Cruz Biotechnology Inc.) was used as a
positive control for AT1R protein. Equal loading was assessed by
reprobing membranes with an antibody to b-actin (1:20 000; Clone
AC-15, Sigma). After overnight incubation, the bound antibody was
detected by enhanced chemiluminescence (Western Lightning
Reagent Plus, Perkin-Elmer Life Sciences, Boston, MA, USA) with
horseradish peroxidase-conjugated goat anti-rabbit immunoglobu-
lin G (No. A-6154, Sigma). Gels were scanned using the Epson
Perfection 1650 scanner and densitometric analysis was performed
with the Imagequant 5.2 software (Molecular Dynamics, Piscataway,
NJ, USA). All values were expressed relative to the average value
of the OVX rats receiving control treatment, arbitrarily assigned
a value of 1.0.
Western blot analysis to detect ER-a and ER-b was performed
using mouse monoclonal antibody to ER-a (ERa-1000, No. SRA-
1000, Stressgen, Victoria, BC, Canada) that recognizes the activated
4S ER-a and not the inactive 8S oligomeric state,38 and rabbit
affinity purified immunoglobulin G antibody to ER-b (No. PA1-
310B, Affinity Bioreagents, Golden, CO, USA), respectively.
Recombinant ER-a (No. 330655, Calbiochem, La Jolla, CA, USA)
and ER-b proteins (No. 330657, Calbiochem) were run as positive
controls.
Immunoprecipitation of AT1R, ER-a, and ER-b proteins
Magnetic immunoprecipitation was performed using the mMACS
system as described by the manufacturer (Miltenyi Biotec, Auburn,
CA, USA). Briefly, kidney cortex was homogenized in radio-
immunoprecipitation assay buffer pH 8.0 (150 mM NaCl, 50 mM
Tris/HCl, 10 mM NaF, 5 mM ethylenediaminetetraacetic acid, 0.1%
sodium dodecyl sulfate, and 1% Nonidet P-40) supplemented with
leupeptin 10 mg/ml, pepstatin A 10 mg/ml, 0.5% deoxycholic acid,
aprotinin 20 mg/ml, protease and phosphatase inhibitor cocktails
(P-5726, P-2850, P-8340, P-2714; Sigma), and 1 mM sodium
orthovanadate. The homogenate (500 mg protein) was incubated
for 1 h on ice with 5 mg of antibody to AT1R (rabbit polyclonal
antibody N-10; No. sc-1173, Santa Cruz Biotechnology Inc.) and
100 ml of protein A-Sepharose magnetic microbeads followed by
application to a microcolumn. The microcolumn was placed in the
field of a magnetic separator, washed sequentially with high and low
salt washes and the samples eluted with 1 boiling laemmli sample
buffer. Eluants were probed for ER-a and ER-b by Western blot.
Double labeling of renal cortex for AT1R, ER-a, and ER-b for
confocal microscopy
Confocal microcopy was performed using tissue snap frozen in
isopentane. Cryosections (10–12 mm) of kidney tissue were air-dried
and fixed with 201C acetone. After a 10-min exposure to 0.5%
Triton X-100 dissolved in PBS, tissue slices were covered for 30 min
with a 0.1 M glycine solution, followed by 10 min with blocking
solution (1% bovine serum albumin in PBS) containing 1% normal,
preimmune serum. After blocking, the tissue slices were incubated at
41C overnight with the following primary antibodies: rabbit
polyclonal AT1R N-10 antibody (sc-1173, Santa Cruz Biotechnology
Inc.), mouse monoclonal AT1R antibody (TONI-1, No. ab9391-1,
Abcam), mouse monoclonal antibody to ER-a (ER-a-1000, No.
SRA-1000, Stressgen), and rabbit affinity-purified immunoglobulin
G antibody to ER-b (No. PA1-310B, Affinity Bioreagents).
The tissue slices were then washed three times with 0.5%
blocking solution in PBS, and incubated for 30 min at 371C with a
secondary antibody or a mixture of antibodies tagged with Alexa
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488 and/or Alexa 568. After the final incubation, the tissue slices
were washed sequentially with PBS and deionized water. The air-
dried slices were mounted with Vectashield mounting medium
(Vector Laboratories Inc., Burlingame, CA, USA) and kept in a dark
cool place.
Confocal microscopy
Sequential images were obtained with a Zeiss LSM 510 confocal
microscope (Zeiss, Jena, Germany). The fluorophors Alexa 488 and
Alexa 568 were excited with the 488 and 543-nm laser lines,
respectively, and the signals collected with a BP filter 505–530 nm for
Alexa 488 and 560–615 nm for Alexa 568. The autofluorescence of
the samples was minimal at the excitation wavelengths and was
subtracted from the values obtained during measurements. When
antibody-blocking peptides were not available, fluorescence pro-
duced without the addition of the primary antibody was subtracted
from that obtained with the primary antibody.
Analysis of mRNA expression by real-time polymerase chain
reaction
Total mRNA was extracted from kidney cortex using the RNeasy
Mini Kit (Qiagen Sciences, Germantown, MD, USA) according to
the manufacturer’s protocol. cDNA was synthesized from 1.5 mg
RNA with the First Strand cDNA Synthesis kit (Amersham
Biosciences, Buckinghamshire, UK). Polymerase chain reaction
amplification reactions were performed in duplicates by ABI Prism
7000 Sequence Detection System (Applied Biosystems, Foster City,
CA, USA) with the QuantiTect SYBR Green PCR kit (Qiagen
Sciences) according to the manufacturer’s protocol. Primers were
designed with Primer Express version 2.0 (Applied Biosystems)
and were synthesized by Sigma-Genosys (Woodlands, TX, USA).
The sequences of the primers used to detect specific genes were
as follows: AT1AR: 5
0-ACCAGGTCAAGTGGATTTCG-30 (forward,
nucleotide 208), 50-ATCACCACCAAGCTGTTTCC-30 (reverse, nu-
cleotide 417); AT1BR: 5
0-ACTGCACACGGTGCATTTTA-30 (for-
ward, nucleotide 97), 50-ATCACCACCAAGCTGTTTCC-30 (reverse,
nucleotide 306). The relative level of mRNA expression of a specific
gene was calculated based on DDCT method according to the
manufacturer’s instruction and normalized to mRNA level for the
housekeeping gene b-actin. The results were confirmed with
Taqman Assay-on-Demand method (Applied Biosystems).
Statistical analysis
The statistical significance of the differences between group means for
the data was determined by one-way analysis of variance followed by
Newman–Keuls post hoc test for multiple comparisons. Correlations
between different parameters were analyzed by simple linear
regression. Differences in means with P-valuesp0.05 were considered
statistically significant. Values are expressed as mean7s.e.
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